Predictive Value and Immunological Role of the HSPA5 Gene in Cervical Cancer

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2024 Apr 7

PMID 38584219

Authors

Yingying Bai

Yandong Miao

Jiangtao Wang

Jian Gan

Jiang Feng

Affiliations

Soon will be listed here.

Abstract

Cervical cancer (CC) ranks fourth among women's malignancies worldwide and seriously affects women's health. HSPA5 is a heat shock protein, also known as glucose regulatory protein 78 (GRP78). Upregulation of HSPA5 has been reported to be closely associated with multiple types of tumors. However, the specific role of HSPA5 in cervical cancer has not been discovered. In our study, we explored the prognostic value of HSPA5 in CC. Here, we analyzed the (TCGA) and (UCSC) databases, the analysis of HSPA5 in many tumors types was conducted with the "wilcox. test" method. A False Discovery Rate (FDR) value < 0.05 and Log2 | (fold change, FC) |> 1 were set as the cutoffs. "*", "**", and "***" indicate FDR < 0.05, < 0.01, and < 0.001, respectively, and further used human cervical cancer cells for q-PCR and western blotting detection. q-PCR and western blotting results showed that HSPA5 was highly expressed in cervical cancer cells, while it was expressed at low levels in normal cells (P < 0.05).We also analyzed the immunohistochemical data. immunohistochemical analysis results showed that HSPA5 was highly expressed in human cervical cancer, while it was expressed at low levels in normal tissues (P < 0.05). Analysis in TCGA-UCSC showed that the proportion of G3 in the group with high expression of HSPA5 was relatively high (P < 0.05). Enrichment analysis and survival analysis showed that the increased expression of HSPA5 in cervical cancer was related to the survival of CC and was involved in the regulation of biological behavior and molecular signaling pathways of cervical cancer. The correlation analysis of immune checkpoint and immune infiltration showed that HSPA5 was involved in the regulation of immune process of cervical cancer (P < 0.05). Drug sensitivity correlation analysis showed that HSPA5 was a sensitive target for tumor drugs (P < 0.05). In brief, those results suggest that HSPA5 can act as an oncogene of CC development and can serve as an effective predictive biomarker in cervical cancer.

References

Abdel Malek M, Jagannathan S, Malek E, Sayed D, Elgammal S, El-Azeem H . Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget. 2015; 6(5):3098-110. PMC: 4413640. DOI: 10.18632/oncotarget.3075. View

Albakova Z, Armeev G, Kanevskiy L, Kovalenko E, Sapozhnikov A . HSP70 Multi-Functionality in Cancer. Cells. 2020; 9(3). PMC: 7140411. DOI: 10.3390/cells9030587. View

Amaresan R, Gopal U . Cell surface GRP78: a potential mechanism of therapeutic resistant tumors. Cancer Cell Int. 2023; 23(1):100. PMC: 10204160. DOI: 10.1186/s12935-023-02931-9. View

Arap M, Lahdenranta J, Mintz P, Hajitou A, Sarkis A, Arap W . Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 2004; 6(3):275-84. DOI: 10.1016/j.ccr.2004.08.018. View

Baxevanis C, Sofopoulos M, Fortis S, Perez S . The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. Cancer Immunol Immunother. 2019; 68(10):1671-1680. PMC: 11028310. DOI: 10.1007/s00262-019-02327-7. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Cai L, Hu C, Yu S, Liu L, Yu X, Chen J . Identification and validation of a six-gene signature associated with glycolysis to predict the prognosis of patients with cervical cancer. BMC Cancer. 2020; 20(1):1133. PMC: 7686733. DOI: 10.1186/s12885-020-07598-3. View

Chang Y, Chiu C, Wu C, An J, Wu C, Liu T . Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010; 17(6):1703-9. DOI: 10.1245/s10434-010-0912-8. View

Chien C, Chen Y, Hsu C, Chou Y, Shiah S, Liu S . YAP-Dependent BiP Induction Is Involved in Nicotine-Mediated Oral Cancer Malignancy. Cells. 2021; 10(8). PMC: 8392082. DOI: 10.3390/cells10082080. View

10.

Cooper O, Bonert V, Rudnick J, Pressman B, Lo J, Salvatori R . EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. J Clin Endocrinol Metab. 2020; 106(2):e917-e925. PMC: 7823257. DOI: 10.1210/clinem/dgaa805. View

11.

French J, Weber Z, Fretwell D, Said S, Klopper J, Haugen B . Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010; 95(5):2325-33. PMC: 2869546. DOI: 10.1210/jc.2009-2564. View

12.

Gaffney D, Winter K, Dicker A, Miller B, Eifel P, Ryu J . A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys. 2006; 67(1):104-9. DOI: 10.1016/j.ijrobp.2006.08.002. View

13.

Herrera F, Chan P, Doll C, Milosevic M, Oza A, Syed A . A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2006; 67(1):97-103. DOI: 10.1016/j.ijrobp.2006.08.024. View

14.

Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A . Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet. 2010; 283(1):109-13. DOI: 10.1007/s00404-010-1389-1. View

15.

Hoque M, Haque E, Karim M . Cervical cancer in low-income countries: A Bangladeshi perspective. Int J Gynaecol Obstet. 2020; 152(1):19-25. DOI: 10.1002/ijgo.13400. View

16.

Hu C, Liu T, Han C, Xuan Y, Jiang D, Sun Y . HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize mA-MYC expression. Int J Biol Sci. 2022; 18(2):507-521. PMC: 8741847. DOI: 10.7150/ijbs.67770. View

17.

Jagannathan S, Abdel-Malek M, Malek E, Vad N, Latif T, Anderson K . Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. Leukemia. 2015; 29(11):2184-91. PMC: 4635337. DOI: 10.1038/leu.2015.157. View

18.

Jia Z, Shen T, Jiang W, Qin H . Identification of molecular mechanisms of glutamine in pancreatic cancer. Oncol Lett. 2017; 14(6):6395-6402. PMC: 5688798. DOI: 10.3892/ol.2017.7068. View

19.

Kagabu M, Nagasawa T, Sato C, Fukagawa Y, Kawamura H, Tomabechi H . Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. Int J Mol Sci. 2020; 21(7). PMC: 7177858. DOI: 10.3390/ijms21072335. View

20.

Kim J, Byun S, Kim Y, Nam J . Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer. Gynecol Oncol. 2016; 144(1):34-39. DOI: 10.1016/j.ygyno.2016.10.032. View